{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-001536","form_type":"8-K","ticker":null,"cik":"0001368620","company_name":"Cann American Corp.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.646030+00:00","generated_at":"2026-06-18T00:19:19.714012+00:00","sec_items":["1.01","2.01","5.02"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Cann American completes acquisition of Prodigy Stem Cell; appoints founder as director","bullets":["Entered binding LOI on Jan 30, 2023 to acquire Prodigy Stem Cell, LLC as wholly owned subsidiary.","Acquisition completed on March 1, 2023; Prodigy becomes wholly owned subsidiary.","Prodigy Stem Cell focuses on sales, marketing, and consulting for regenerative medicines.","Peter Caruso, founder of Prodigy, appointed as director effective March 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-001536","json":"https://secwatch.observer/filing/0001683168-23-001536.json","markdown":"https://secwatch.observer/filing/0001683168-23-001536.md","text":"https://secwatch.observer/filing/0001683168-23-001536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368620/000168316823001536/0001683168-23-001536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368620/000168316823001536/cann_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:19:19.714012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32b727f656","claim":"Peter Caruso was appointed as Director at Cann American Corp..","evidence_excerpt":"On March 1, 2023, the Company appointed Peter Caruso as a Director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368620/000168316823001536/0001683168-23-001536-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f05dbdc2b554ddda3fb4564b977ff636a691f937","claim":"Cann American Corp. completed an acquisition involving Prodigy Stem Cell, LLC (closed 2023-03-01).","evidence_excerpt":"On March 1, 2023, the Company completed the acquisition of Prodigy Stem Cell, LLC as a wholly owned subsidiary.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368620/000168316823001536/0001683168-23-001536-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Prodigy Stem Cell, LLC"},{"label":"Closing","value":"2023-03-01"}],"fact_type":"ma_transaction"},{"claim_id":"965545ae6b78e31489ead9bd8d9f4be4199f3d75","claim":"Cann American Corp. entered into Binding Letter of Intent with Prodigy Stem Cell, LLC (effective 2023-01-30).","evidence_excerpt":"Item 1.01 Entry into a Material Definitive Agreement. On January 30, 2023, the Company entered into a Binding Letter of Intent to acquire Prodigy Stem Cell, LLC as a wholly owned subsidiary of the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368620/000168316823001536/0001683168-23-001536-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Prodigy Stem Cell, LLC"},{"label":"Effective","value":"2023-01-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}